MIRA — MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 2
- Website: https://mirapharmaceuticals.com
Latest SEC filings for MIRA
- 8-K — 2026-09-01
- 10-Q — 2026-08-12
- 8-K — 2026-08-06
- 8-K — 2026-07-31
- 8-K — 2026-07-10
- 8-K — 2026-07-06
- 8-K — 2026-06-25
- 8-K — 2026-06-17
- 8-K — 2026-06-08
- 8-K — 2026-06-04
Latest MIRA news
- — MIRA MATTER Introduces First-of-Its-Kind Living Memory, Transforming Pet Fur at the Molecular Level to Carry Forward Into New Life and Light (prnewswire_financial)
Educational tool only — not investment advice.